Categories
BLOG

cannabis nebulizer

Pearl2O Nebulizer

Pearl2o™ NEBULIZER SYSTEM

Leading the Evolution of Cannabis Delivery

The Pearl2o™ Nebulizer System is specifically designed for exclusive use with Pearl2o™ Vitamin Water based applications.

Pearl2o™ Nebulizer System Benefits:

  1. Fast and precise delivery medical grade, smoke-free and oil-free delivery of cannabis
  2. Extremely gentle delivery with no cannabis taste, odor, or flavor
  3. Discrete, quick and timely delivery of water-based medical and non-medical cannabis applications and products
  • Virtually silent operation
  • Extremely compact and portable
  • Powered by a single set of AA batteries
  • Available optional AC adapter
  • Medical grade and BPA-free components
Pearl2o™ Nebulizer System and PEARL2O™ water are powered by is by Sōrse™, a one-of-its-kind Advanced Cannabis Emulsion technology.
Sōrse™ and Pearl2o™ vitamin water enable the delivery of smoke-free and oil-free, water-based, medical grade cannabis experiences.
PLEASE CONTACT US FOR MORE INFORMATION AT [email protected]

Sign up for our newsletter:

Washington Disclaimer: This product has intoxicating effects and may be habit forming. Marijuana can impair concentration, coordination, and judgement. Do not operate a vehicle or machinery under the influence of this drug. There may by health risks associated with consumption of this product. For use only by adults twenty-one and older. Keep out of reach of children. Washington State 502 Pesticide Disclaimer: No Pesticides were used in the cultivation, extraction, or infusion of this product.

CA license(s): Rec: CDPH-T00000697, Med: CDPH-T00000696

All rights reserved. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the publisher, except in the case of brief quotations embodied in critical reviews and certain other noncommercial uses permitted by copyright law.

Pearl2O Nebulizer Pearl 2 o ™ NEBULIZER SYSTEM Leading the Evolution of Cannabis Delivery The Pearl 2 o ™ Nebulizer System is specifically designed for exclusive use with Pearl 2 o ™

Cannabis Science Develops Inhalation Medication for Those Suffering Asthma/COPD via Nebulizer, Targets National Markets

IRVINE, CA–(Marketwired – Jul 29, 2016) – Cannabis Science, Inc. ( OTC PINK : CBIS ), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce they will release an inhalation medication for those suffering asthma/COPD for use in patient nebulizers. This product will be offered in states where marijuana is legal on a national basis.

Based on State by State laws the Company can proceed with studies in the 25+ states approved for medical marijuana, and lay the groundwork for expanding into other states across the nation as legislation changes and more states become legal. This could also be seen as a mechanism to verify the effectiveness of CBD/THC on patients that use the medication as a bronchodilator.

Studies have shown CBD/THC to be effective as a bronchial dilator and in many cases being better that Albuterol or Ipratropium.

Studies have demonstrated that THC may act as a temporary (1-2 hours) bronchodilator, especially when ingested. The New England Journal of Medicine, published a 1973 study that stated, “Marihuana smoke, unlike cigarette smoke, causes broncho-dilation rather than broncho-constriction [narrowing of the air passages] and, unlike opiates, does not cause central respiratory depression [i.e. a decrease in breathing].”

Another long-term study (20 years) done from 1985 to 2006, examined 5,000 subjects from three American cities. The researchers questioned the participants about their cannabis and cigarette use, and tested lung capacity as well as rate of air flow out of their lungs. To their surprise, the researchers found that at low to moderate levels of cannabis smoking, lung volume and air flow rates both increased with each “joint year” (365 joints), up until seven joint-years (or 2,555 joints).

Bronchodilatory effects – Studies performed in the 1970’s at the University of California Los Angeles by Donald Tashkin have shown that both inhaled and orally ingested THC produce bronchodilation for up to two hours after administration [1] . Further investigations by the Respiratory Pharmacology Laboratory in Paris have shown that CB1 receptor activation inhibits cholinergic contraction in a concentration-dependent fashion, offering a possible mechanism for acute bronchodilation associated with cannabis intake [2] . Although smoked cannabis also has this effect, any kind of combustion creates other lung irritants that would be counterproductive for COPD treatment.

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that makes it difficult to breathe. “Progressive” means that the disease gets worse over time.

Approximately 12 million people in the United States have been diagnosed with COPD. Many more may be affected and not know they have it.

CHRONIC OBSTRUCTIVE PUMONARY DISEASE (COPD) LUNG FUNCTION & CANNABIS STUDIES COMPLETED

Marijuana has long been reported to relieve symptoms of asthma. Now, research explains why marijuana’s main ingredient may help patients breathe easier.

How Cannabinoids may help COPD

  • Cannabinoids relieve inflammation
  • Cannabinoids are anti-microbial
  • Cannabinoids support / modulate the immune system and its response to infection and disease
  • Cannabinoids are expectorants
  • Cannabinoids are analgesic (pain relief)
  • Cannabinoid medicine has little to no side effects

In COPD, air flow is restrictive due to:

  • The airways + air sacs have a lack of elasticity
  • Air sac destruction and inflammation
  • Increased mucus and clogged airways

Published last week in the British Journal of Pharmacology, a new study shows marijuana may have a similar effect on the airways as some asthma medications.

Using samples of human lung tissue, French researchers found that THC could block muscle contractions caused by a signaling molecule called acetylcholine.

Acetylcholine is responsible for maintaining muscle tone of the airways and also contributes to contractions in asthma attacks. Interestingly, asthma medications block the same molecule, but from a slightly different angle.

“They prevent the acetylcholine from binding to its receptor,” explains Dr. Donald Tashkin, who was not involved with the study. “But THC works proximal to that. It doesn’t have any competitive effect for binding to receptors. It just prevents the acetylcholine from being released.”

Dr. Donald Tashkin, a lung expert and professor of medicine at UCLA, was part of the team that first discovered marijuana’s effect as a bronchodilator. In 1973, his group published a study in the New England Journal of Medicine that found airways widen in both healthy and asthmatic individuals after smoking marijuana.

“It also succeeded in reversing experimentally induced asthma, in a manner that was comparable to what could be achieved with a standard therapeutic bronchodilator that was widely used at the time.”

Dr. Tashkin explains, “I don’t know if anyone’s ever studied the effect of vaporized THC on airway smooth muscle, but my guess is that it would lead to bronchodilation.”

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of a unique understanding of biologic processes to provide novel treatment approaches for common ailments and for those disorders where current treatments are relatively unsuccessful and understanding remain incomplete. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the increasingly complex underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

IRVINE, CA–(Marketwired – Jul 29, 2016) – Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based…